APA (7th ed.) Citation

Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, . . . Grzegorz Kamiński. (2023). Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade. MDPI AG.

Chicago Style (17th ed.) Citation

Adam Daniel Durma, Marek Saracyn, Maciej Kołodziej, Katarzyna Jóźwik-Plebanek, Beata Dmochowska, Adrianna Mróz, Wawrzyniec Żmudzki, and Grzegorz Kamiński. Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade. MDPI AG, 2023.

MLA (9th ed.) Citation

Adam Daniel Durma, et al. Radioligand Therapy with [¹⁷⁷Lu]Lu-DOTA-TATE or [¹⁷⁷Lu]Lu-DOTA-TATE and [⁹⁰Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade. MDPI AG, 2023.